Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452686
Status:
COMPLETED
Last Update Posted:
2016-10-28
First Post:
2007-03-26
Brief Title:
Study to Assess Safety Immunogenicity of GSK Biologicals Boostrix dTpa Vaccine vs Chinese DT Vaccine
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Immunogenicity and Safety Study of GlaxoSmithKline GSK Biologicals Boostrix dTpa Vaccine and the Chinese DT Vaccine When Administered as Booster Vaccination in Healthy Children Aged 6-8 Years
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and immunogenicity of a booster dose of GSK Biologicals reduced antigen content diphtheria tetanus acellular pertussis dTpa vaccine - Boostrix in comparison with Chinese DT vaccine in children 6-8 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None